HCV elimination:is the bulk of the iceberg being missed?  

作　　者：Eric Kalo Asma Baig Alison Derrett Scott Read Golo Ahlenstiel 

机构地区：[1]Blacktown Clinical School,School of Medicine,Western Sydney University,Blacktown,NSW,Australia [2]Blacktown Mount Druitt Hospital,Western Sydney Local Health District,Blacktown,NSW,Australia [3]Western Sydney Local Health District,Westmead,NSW,Australia [4]Storr Liver Centre,The Westmead Institute for Medical Research,University of Sydney,Westmead,NSW,Australia

出　　处：《Gastroenterology Report》2024年第1期854-856,共3页胃肠病学报道(英文)

基　　金：Ethics approval was obtained from the Human Research Ethics Committee at Western Sydney Local Health District(Ethics Approval 2021/ETH00149).

摘　　要：Introduction In 2016,the Australian government spent more than 1 billion dollars to make hepatitis C virus(HCV)direct-acting antivirals(DAAs)available to all as part of a promising plan to eradicate HCV within a generation[1].Moreover,Australia's unique approach of offering well-tolerated pan-genotypic DAAs(sofosbuvir/velpatasvir,glecaprevir/pibrentasvir)through general practitioners has significantly increased treatment accessibility.

关 键 词：ELIMINATION offering DOLLAR 

分 类 号：R51[医药卫生—内科学]